Loading...

AFL: Earnings Stability And Strong Buybacks Will Support Balanced Outlook

Published
06 Aug 24
Updated
01 May 26
Views
351
01 May
US$117.86
AnalystConsensusTarget's Fair Value
US$111.86
5.4% overvalued intrinsic discount
Loading
1Y
15.0%
7D
-0.7%

Author's Valuation

US$111.865.4% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 01 May 26

AFL: Future Returns Will Balance Reinsurance Moves With Cautious Earnings Expectations

Narrative Update on Aflac

The consensus analyst price target for Aflac has edged lower by a few dollars to $111.86, as analysts factor in more cautious revenue growth assumptions alongside slightly stronger profit margin and future P/E inputs.

Analyst Commentary

Recent research on Aflac reflects a mixed but mostly cautious tone, with several firms trimming price targets by small amounts and one lifting its target and reinitiating coverage at a neutral stance. For you as an investor, the key signals are around how analysts are thinking about valuation, earnings power, and execution over the next few years.

Bullish Takeaways

  • Bullish analysts who raised targets toward $118 and reinitiated coverage with neutral ratings highlight that Aflac’s earnings profile supports using longer term EPS estimates, including 2027 and 2028, in valuation work.
  • The decision by bullish analysts to roll their models to 2027 EPS and introduce 2028 estimates signals that they see Aflac as having enough earnings visibility to anchor multi year projections, which can help support the current P/E framework.
  • Target increases of a few dollars suggest some analysts see room for modest upside relative to prior expectations, even as they keep ratings such as Equal Weight or Market Perform. This points to a balanced risk reward rather than a high risk profile.

Bearish Takeaways

  • Bearish analysts lowering price targets by US$2 to US$5 indicate reduced conviction in upside, with valuation being reset closer to what they view as more conservative earnings assumptions.
  • Several target cuts clustered in a short window imply that multiple analysts are reassessing revenue growth and margin assumptions at the same time, which can cap how much P/E expansion they are willing to assign.
  • Commentary that EPS estimates are being reduced for many companies, including Aflac, points to concern that prior earnings baselines were too optimistic, and that investors should pay close attention to how future guidance lines up with these revised models.
  • The mix of small target cuts and neutral ratings suggests cautious analysts see limited near term catalysts to materially re rate the shares. This keeps expectations for execution and growth more muted in their models.

What's in the News

  • Aflac Re Bermuda Ltd. agreed with Japan Post Insurance Co. Ltd. to reinsure a block of whole life annuities through coinsurance. Japan Post Insurance will continue to service and administer the policies. The transaction is effective March 31, 2026 (Key Developments).
  • Aflac added a long term care rider to its Group Life Term to 120 product. The rider offers term life coverage combined with long term care benefits that can be used for home based or facility based care and allows flexibility in caregivers, payment options, and portability, subject to state availability and underwriting entities (Key Developments).
  • Empower Brokerage began an affiliation with Aflac, giving more than 8,000 partnering agents the ability to sell Aflac individual and group policies. Empower will provide support on contracting, commissions, and bonuses (Key Developments).
  • From October 1, 2025 to December 31, 2025, Aflac repurchased 7,249,599 shares, representing 1.38%, for US$800.12m. This completed the buyback of 265,676,748 shares, representing 41.51%, for US$17.66772b under the program announced on August 8, 2017 (Key Developments).

Valuation Changes

  • Fair Value: The estimated fair value remains unchanged at $111.86, so there is no adjustment to the implied intrinsic value per share.
  • Discount Rate: The discount rate is stable at 6.98%, indicating no shift in the required return used in the valuation model.
  • Revenue Growth: The long term revenue growth assumption has moved from 1.46% growth to a 0.14% decline. This reflects a more cautious view on top line expansion.
  • Net Profit Margin: The net profit margin input has nudged higher from 20.75% to 20.86%, pointing to slightly stronger expected profitability on each dollar of revenue.
  • Future P/E: The future P/E multiple used in the model has inched up from 16.53x to 16.67x, suggesting a modestly higher valuation multiple on projected earnings.
1 viewusers have viewed this narrative update

Key Takeaways

  • Product innovation and digitalization expand Aflac's market reach, support topline growth, and improve operational efficiency and customer engagement.
  • Investment portfolio diversification and new distribution strategies enhance earnings stability and drive sustained long-term income growth.
  • Heavy reliance on Japan and challenging investment returns, along with weak U.S. sales growth, pose ongoing risks to Aflac's revenue, earnings, and margin stability.

Catalysts

About Aflac
    Through its subsidiaries, provides supplemental health and life insurance products.
What are the underlying business or industry changes driving this perspective?
  • The successful launch of new, customizable cancer insurance (Miraito) in Japan, coupled with strong early sales across all distribution channels-including banks and Japan Post-positions Aflac to capture growing demand for supplemental health coverage among aging and younger consumers, supporting topline revenue and premium growth.
  • Increased adoption of digital underwriting, customer-facing Gen AI, and digital human avatar initiatives in both Japan and the U.S. is expected to lower long-term operational costs and improve customer engagement, with the potential to materially expand net margins through enhanced efficiency and better scalability.
  • Heightened consumer awareness of financial health risks and rising medical costs-combined with product innovation (such as modular coverage, new children's cancer policies, and expanded group dental/vision)-broadens Aflac's addressable market and increases cross-sell opportunities, supporting both revenue and persistency.
  • Ongoing diversification and optimization of Aflac's investment portfolio, including the proactive management of yen
  • and USD-denominated assets, positions the company to better withstand interest rate cycles and enhance investment income stability, reducing earnings volatility and supporting sustainable bottom-line growth.
  • Strategic expansion in digital direct-to-consumer channels in the U.S., aggressive agent recruitment in Japan, and new partnerships with large institutions (like state-run disability leave programs) enable Aflac to extend market reach and drive sustained earned premium and fee-based income growth over the long term.
Aflac Earnings and Revenue Growth

Aflac Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Aflac's revenue will remain fairly flat over the next 3 years.
  • Analysts assume that profit margins will shrink from 25.6% today to 20.9% in 3 years time.
  • Analysts expect earnings to reach $3.8 billion (and earnings per share of $8.27) by about May 2029, down from $4.6 billion today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.7x on those 2029 earnings, up from 12.4x today. This future PE is greater than the current PE for the US Insurance industry at 11.7x.
  • Analysts expect the number of shares outstanding to decline by 4.06% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  •  Net earned premiums in Japan, Aflac's largest and most profitable market, continued to decline year-over-year (down 1.1% excluding one-off effects), and management's guidance recognizes ongoing negative premium growth of -1% to -2% for the foreseeable future, which could constrain future revenue and earnings growth.
  •  The company is experiencing increased technology and expense ratios in Japan (up 280 basis points year-over-year), largely due to digital transformation initiatives; if these investments do not translate into commensurate productivity gains, net margins may remain under pressure.
  •  Aflac's significant exposure to Japan subjects it to persistent currency fluctuations and economic uncertainty-yen depreciation directly impacts reported USD earnings and the efficacy of capital deployment (including 65% of debt held in yen), increasing volatility in both reported revenue and earnings per share.
  •  Variable net investment income was materially below long-term targets in the quarter (down 10.5% in yen terms for Japan), highlighting the ongoing risk from persistent low global bond yields and challenging investment environments, which could lead to lower investment returns and net margins over the long-term.
  •  Persistent sluggishness in U.S. sales (only a 2.7% year-over-year increase), still not at historical growth rates, and dependence on agent recruitment and effectiveness in the traditional distribution channel, points to execution risk; failure to reinvigorate U.S. sales growth may limit future revenue expansion and earnings diversification.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $111.86 for Aflac based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $126.0, and the most bearish reporting a price target of just $97.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $18.0 billion, earnings will come to $3.8 billion, and it would be trading on a PE ratio of 16.7x, assuming you use a discount rate of 7.0%.
  • Given the current share price of $112.88, the analyst price target of $111.86 is 0.9% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Aflac?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives